MR urography: Anatomical and quantitative information on congenital malformations in children.

BACKGROUND AND AIM: Magnetic resonance urography (MRU) is considered to be the next step in uroradiology. This technique combines superb anatomical images and functional information in a single test. In this article, we aim to present the topic of MRU in children and how it has been implemented in Northern Greece so far. The purpose of this study is to demonstrate the potential of MRU in clinical practice. We focus both on the anatomical and the quantitative information this technique can offer. MATERIALS AND METHODS: MRU was applied in 25 children (ages from 3 to 11 years) diagnosed with different types of congenital malformations. T1 and T2 images were obtained for all patients. Dynamic, contrast-enhanced data were processed and signal intensity versus time curves were created for all patients from regions of interest (ROIs) selected around the kidneys in order to yield quantitative information regarding the kidneys function. RESULTS: From the slopes of these curves we were able to evaluate which kidneys were functional and from the corticomedullary cross-over point to determine whether the renal system was obstructed or not. CONCLUSION: In all 25 cases MRU was sufficient, if not superior to other imaging modalities, to establish a complete diagnosis.

SPECT imaging evaluation in movement disorders: far beyond visual assessment.

Single photon emission computed tomography (SPECT) imaging with (123)I-FP-CIT is of great value in differentiating patients suffering from Parkinson's disease (PD) from those suffering from essential tremor (ET). Moreover, SPECT with (123)I-IBZM can differentiate PD from Parkinson's "plus" syndromes. Diagnosis is still mainly based on experienced observers' visual assessment of the resulting images while many quantitative methods have been developed in order to assist diagnosis since the early days of neuroimaging. The aim of this work is to attempt to categorize, briefly present and comment on a number of semi-quantification methods used in nuclear medicine neuroimaging. Various arithmetic indices have been introduced with region of interest (ROI) manual drawing methods giving their place to automated procedures, while advancing computer technology has allowed automated image registration, fusion and segmentation to bring quantification closer to the final diagnosis based on the whole of the patient's examinations results, clinical condition and response to therapy. The search for absolute quantification has passed through neuroreceptor quantification models, which are invasive methods that involve tracer kinetic modelling and arterial blood sampling, a practice that is not commonly used in a clinical environment. On the other hand, semi-quantification methods relying on computers and dedicated software try to elicit numerical information out of SPECT images. The application of semi-quantification methods aims at separating the different patient categories solving the main problem of finding the uptake in the structures of interest. The semi-quantification methods which were studied fall roughly into three categories, which are described as classic methods, advanced automated methods and pixel-based statistical analysis methods. All these methods can be further divided into various subcategories. The plethora of the existing semi-quantitative methods reinforces the feeling that visual assessment is still the base of image interpretation and that the unambiguous numerical results that will allow the absolute differentiation between the known diseases have not been standardized yet. Switching to a commonly agreed-ideally PC-based-automated software that may take raw or mildly processed data (checked for consistency and maybe corrected for attenuation and/or scatter and septal penetration) as input, work with basic operator's inference and produce validated numerical results that will support the diagnosis is in our view the aim towards which efforts should be directed. After all, semi-quantification can improve sensitivity, strengthen diagnosis, aid patient's follow-up and assess the response to therapy. Objective diagnosis, altered diagnosis in marginal cases and a common approach to multicentre trials are other benefits and future applications of semi-quantification.

[Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].

Gastro-entero-pancreatic tumors (GEP) contain, in their majority, somatostatin receptors. In-111-DTPA-phenyl-pentetreotide has been proved to have high affinity for somatostatin receptors subtypes 2, 3 and 5. The aim of the present study was to evaluate the utility of (111)In-DTPA-O somatostatin receptors' scintigraphy (SRS) in the diagnosis of suspected GEP. Thirty-five consecutive patients (17 males and 18 females-mean age 57.9+/-7.6) with GEP as a possible diagnosis were enrolled in the study. The primary diagnosis was diarrheic syndrome susceptive of intestinal carcinoid tumor (24 patients), carcinoid of the rectum (2 patients), adenocarcinoma of the pancreas (2 patients), insulinoma (2 patients), gastrinoma (3 patients) and hepatocellular carcinoma (2 patients). All patients were submitted to computerized tomography (CT) of the thorax and the abdomen and pentetreotide SRS was performed 4 h (total body and SPET acquisition) and 24 h (planar views), post iv injection of 185 MBq of the radiolabeled compound. Results showed: Four of the patients were false positive diagnosed as having inflammatory intestinal disease and gallbladder dilatation. At the time of the evaluation, 14 of the remaining patients were free of disease, concerning secondary involvement. In these cases, CT and SRS studies matched each other, with no pathological lesions and no abnormal accumulation of the radiopharmaceutical respectively. Concerning pathological cases, only one SRS study in a patient with rectum carcinoid was normal, with liver lesions in the CT study. These lesions were considered as subtypes 2, 3 and 5 somatostatin receptors negative. SRS revealed three lesions more than CT. According to these results, sensitivity of SRS study was 93.8% and specificity 86.9%. The authors believe that molecular imaging of somatostatin receptors, is a sensitive method for the evaluation of patients with GEP tumors. However, in cases of intestinal disease, we should be aware of false positive results due to inflammatory processes and the presence of lymphocyte infiltration.

Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography.

Extrapyramidal symptoms are observed in frontotemporal dementia (FTD). (123)I-FP-CIT (DaT scan) single photon emission computed tomography (SPECT) can detect loss of presynaptic dopamine transporters in the striatum. We aimed to evaluate the dopaminergic status of the striatum in patients with FTD using DaT scan. Seven patients (age range 65-76 years), who fulfilled the Neary criteria and in whom the diagnosis of FTD was confirmed by hexamethylpropyleneamine oxime SPECT, were included in the study. The severity of the extrapyramidal symptoms was evaluated by the motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). SPECT using (123)I-FP-CIT was done. A (region - occipital)/occipital ratio was calculated for the striatum, putamen and caudate nucleus. The results were compared with those of the 7 age-matched normal controls. The uptake of the radiotracer in the right and left striatum was reduced to 62% (p = 0.000) and 68% (p = 0.000), respectively, compared to controls. The motor UPDRS score of the patients with FTD showed a negative correlation to the uptake of the radiotracer. The presynaptic dopamine transporter in FTD is impaired, related to the severity of the extrapyramidal symptoms. Since an effective treatment for FTD is still to be established, there is a need for evaluating the efficacy of dopaminergic drugs.

The variation of intrinsic spatial resolution across the UFOV of scintillation cameras.

The aim of the present study was to investigate in detail the variation of the intrinsic spatial resolution across the useful field of view (UFOV) of gamma-cameras and to explore whether this variation could lead to observable effects in clinical images. Two gamma-cameras were used, without their collimators, to acquire 560 (99m)Tc point source images at different points across their UFOVs, in order to measure the intrinsic spatial resolution at each point. Possible clinical effects of the resolution variation were examined on images of a thyroid phantom using a LEHR collimator, acquired at different locations on the UFOV and at various distances from the collimator. The gamma-camera intrinsic resolution varied significantly across the UFOV, being generally lower at the central region and deteriorating at the edges. Pronounced local maxima and minima were found at points corresponding to the centers of the photomultiplier tubes (PMTs) and halfway in between. Maximum differences of more than 50% were observed between the points presenting the best and worst intrinsic resolution. Differences between neighboring points reached 17%. The effects of resolution variation were clearly observable on the thyroid phantom images. It was concluded that an appropriate correction algorithm might be necessary in order to correct for the variation of the intrinsic spatial resolution across the UFOV of gamma-cameras.

Tc-99m depreotide imaging of I-131-negative recurrent metastatic papillary thyroid carcinoma.

The detection of radioiodine (I-131)-negative metastases of differentiated thyroid carcinoma (DTC) has been hitherto successfully tried by the well-known synthetic somatostatin analogue indium-111-labeled DTPA-octreotide (In-111 pentetreotide). The objective of this study was to evaluate the usefulness of scintiscan with the newer synthetic somatostatin analogue Tc-99m depreotide, in the restaging of papillary thyroid carcinoma (PTC) with detectable serum thyroglobulin (Tg) levels and negative I-131 whole-body scan (WBS). Whole-body planar and cervico-thoracic tomographic scintigraphy (single-photon emission tomography-SPET) with Tc-99m depreotide was performed in a 68-year-old male patient suffering from PTC stage III, with a mild increase in serum Tg levels coupled with a recent negative I-131 WBS. The findings were compared with those of neck ultrasonography (US) and computerized tomography (CT). Nodal neck dissection and histopathology provided the definitive diagnosis. Tc-99m depreotide scanning revealed foci of cervical lymph node metastases, which did not accumulate I-131. The findings were in accordance with neck US and CT. Histopathology established the diagnosis of metastatic cervical lymph node PTC. Lymph node immunoreactivity was positive for the somatostatin receptor subtypes 2, 5 and 3. Scintigraphy with Tc-99m depreotide could prove a useful adjunct to the armamentarium for the follow-up of PTC, especially in the setting of detectable serum Tg and negative I-131 WBS.

Skin doses to patients undergoing coronary angiography in a Greek hospital.

In this study, the skin dose (SD) to patients undergoing coronary angiography (CA) were measured with thermoluminescence dosemeters (TLD) attached to various anatomical locations on the patient's skin during 93 CA procedures in a Greek hospital. The dose-area product (DAP) for every radiological projection was also measured for each procedure. The SD values were measured to be in the range 2.4-427.5 mGy, lower than the 2 Gy dose threshold for transient erythema. No general correlation was observed between the SD and the total DAP.

The dependence of patient dose on factors relating to the technique and complexity of Interventional Cardiology procedures.

Dose-area product (DAP) measurements were conducted for 168 coronary angiography (CA) and 89 single vessel percutaneous transluminal coronary angioplasty (PTCA) to examine the factors influencing patient dose beyond the X-ray exposure parameters. It was found that for CA, the DAP increases with the number of catheters used and with the number of vessels with stenosis. DAP values for patients with a prior bypass surgery, were higher compared to those without such a medical record to surgery. In PTCA, the use of coronary stents did not enhance the patient radiation dose significantly. Noticeable differences were found in the percentage contribution of each projection to the total DAP between the three types of single vessel PTCA. Finally low variations in DAP were found among the cardiologists performing both procedures.

Oprimizing the protocol for the calculation of the doses of (131)I administered for the treatment of benign thyroid disease.

The administration of (131)I for the treatment of benign thyroid disease is widely used in clinical practice. The appropriate dose of (131)I, so as the gland could receive the specified absorbed dose, is determined by various methods. The mostly used is the one based on the 24 h uptake. In the present study we examined the time to measure (131)I uptake which better represents the total accumulated activity in the thyroid gland and consequently is more reliable for dose calculation. Fourteen patients, who were referred to the Nuclear Medicine Department of AHEPA University Hospital, were included in the study. 1.85 MBq of (131)I were administered and the uptake at 24, 48, 72 and 192 h was measured. From the curve of the activity vs time we calculated the area under it, which represents the total accumulated thyroid activity. We compared the uptakes of every individual with the total area and we found that the 192 h uptake was best correlated with it (r=0.996). The absorbed dose to the thyroid was calculated in the following ways: a) was based on the 24 h uptake and b) was based on the total accumulated activity on the 192 h uptake. We found differences from -19.9% to +33.7%. In conclusion, the 192 h uptake consists the most representative and reliable parameter for the estimated activity of (131)I given to the thyroid for the treatment of hyperthyroidism.

[A patient with MEN-IIA syndrome due to de novo mutation and papillary thyroid carcinoma; the role of 99m Tc-depreotide in diagnosing metastases and brief review of the literature]. / In Process Citation.

Multiple endocrine neoplasia syndrome type II-A (MEN-IIA) is a rare endocrinological disorder occurring in 0.04% of the general population. The combination of papillary thyroid carcinoma with MEN-IIA appears even less frequently. We describe the case of a 21-year-old woman with pheochromocytoma of the left adrenal gland, medullary thyroid carcinoma, hyperplasia of the parathyroid glands and papillary thyroid carcinoma. MEN II-A syndrome resulted from de novo mutation of the RET proto-oncogene, which was detected in the DNA of peripheral blood leucocytes. Three months postoperatively calcitonin levels were normal, whilst increased serum thyroglobulin values prompted the need for further investigation. Whole body scanning with (131)I and with (99m)Tc-sestamibi and also US test of cervical lymph nodes, were negative. The synthetic analogue of somatostatin (99m)Tc-depreotide was used for whole body scintigraphy, cervical and thoracic tomographic scanning and revealed anterior cervical, upper mediastinal and right hilar foci of pathological uptake[Fig.1 and Table 1: see text]. These findings were compatible with findings from CT and MRI that followed in order to complete the diagnostic evaluation. The patient underwent surgical resection of the metastatic foci with uneventful postoperative course. Histology showed lymph node metastases originating from the papillary thyroid carcinoma. Ratio values >2 were abnormal (Fig. 2). Computer processing of the corresponding ROIs on healthy tissues produced the following normal values: Th/Arm: 1.874,, Med/Arm: 1.699, Hi/Arm: 1.141 (Fig. 3).

Radiation exposure to cardiologists performing interventional cardiology procedures.

Medical doctors, who practice interventional cardiology, receive a noticeable radiation dose. In this study, we measured the radiation dose to 9 cardiologists during 144 procedures (72 coronary angiographies and 70 percutaneus translumined coronary angioplasties) in two Greek hospitals. Absorbed doses were measured with TLD placed underneath and over the lead apron at the thyroid protective collar. Based on these measurements, the effective dose was calculated using the Niklason method. In addition, dose area product (DAP) was registered. The effective doses, E, were normalised to the total DAP measured in each procedure, producing the E/DAP index. The mean effective dose values were found to be in the range of 1.2-2.7 microSv while the mean E/DAP values are in the range of 0.010-0.035 microSv/Gycm2. The dependence of dose to the X-ray equipment, the exposure parameters and the technique of the cardiologist were examined. Taking under consideration the laboratories' annual workload, the maximum annual dose was estimated to be 1.9 and 2.8 mSv in the two hospitals.